Uncultured adipose-derived regenerative cells - ADRCs?
Can anyone with expert knowledge of this subject improve this to
be read better as a definition for the laymen! This has been taken
from an article on Monday 14 September 2009 (www.reuters.com).
Thanks! >>>>> "Cytori Reports Preclinical Results
that Suggest Adipose-Derived Regenerative Cells may Reverse
Periodontal Disease: >>>>> Cytori Therapeutics
(NASDAQ:CYTX) reported results from their preclinical study on the
use of uncultured adipose-derived regenerative cells (ADRCs) in the
treatment of critical periodontal defects in a rat model. The
results suggest that the use of ADRCs may reverse the effects of
periodontal disease, evidenced by significantly improved alveolar
bone healing and decreased gingiva(gum) invasion of the defect. The
data were reported today at the 95th Annual Meeting of the American
Academy of Periodontology in Boston. >>>>> Severe
periodontal disease (periodontitis) affects over 25% of the
population in the U.S. alone. It is a painful condition that
results in the decay of the bone and connective tissue that
surround teeth that can ultimately lead to tooth loss. Currently,
there is no generally accepted treatment with reliable results.
These new study findings by Cytori may lead to new therapeutic
treatments using ADRCs to treat and potentially reverse the effects
of severe periodontitis. >>>>> As part of the study
design, 20 immuno-deficient rats were treated for four critical
defects in each. One of the defects was treated with uncultured
human ADRCs and a second with cultured human adipose-derived stem
cells (ADSC`s), both in Platelet Rich Plasma (PRP). A third was
treated with PRP alone and a fourth with no
treatment.>>>>> The study`s results showed that at
six weeks post-treatment the defects treated with the uncultured
ADRCs and with the cultured ADSCs showed a statistically
significant (p>> About Cytori Cytori is committed to
providing patients and physicians around the world with medical
technologies, which harness the potential of adult stem and
regenerative cells from adipose tissue. With the introduction of a
family of medical devices, we have made a patient's own clinical
grade stem and regenerative cells available to them at the
point-of-care. The Celution® System family of medical devices and
instruments is being sold into the European and Asian cosmetic and
reconstructive surgery markets, while we seek regulatory clearance
for it in the United States. Our StemSource® product line is sold
globally for cell banking and research applications.
www.cytoritx.com >>>>> Cautionary Statement
Regarding Forward-Looking Statements >>>>> This
press release includes forward-looking statements regarding events,
trends and business prospects, which may affect our future
operating results and financial position. Such statements are
subject to risks and uncertainties that could cause our actual
results and financial position to differ materially. Some of these
risks and uncertainties include our history of operating losses,
the need for further financing, regulatory uncertainties regarding
the collection and results of, clinical and pre-clinical data,
dependence on third party performance, and other risks and
uncertainties described under the "Risk Factors" in Cytori's
Securities and Exchange Filings, including its annual report on
Form 10-K for the year ended December 31, 2008. Cytori assumes no
responsibility to update or revise any forward-looking statements
contained in this press release to reflect events, trends or
circumstances after the date of this press
release.">>>>> Cytori Therapeutics Tom Baker,
858-875-5258 tbaker@cytoritx.com >>>>> ~End of
extract. 31 October 2009.~ >>>>>
